Grand Pharmaceutical Group (HKG:0512) said the first patient was enrolled in its clinical study of GPN00289 in China, a temperature-sensitive embolic agent for advanced liver cancer treatment, according to a Thursday filing with the Hong Kong bourse.
The study assesses the safety and efficacy of the treatment, which combines GPN00289 drug delivery and embolization.
The company's shares were down by 1% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。